Eledon Pharmaceuticals (ELDN)
Develops tegoprubart for transplant rejection and CD40L-linked immune disease.
$3.06
Pre-market+0.08 (+2.51%)
At close$2.99(−0.83%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
in 71 days
EPS estimate
−$0.20
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.64−$0.08−$0.13−$0.21−$0.10−$0.16−$0.27Pending
Estimate−$0.32−$0.28−$0.23−$0.22−$0.20−$0.22−$0.16−$0.20
Surprise−100.0%+71.4%+43.5%+4.5%+50.0%+27.3%−70.9%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$192.0K——————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.20 | — | — |
| Aug 2026 | −$0.16 | −$0.27 | −70.9% |
| May 2026 | −$0.22 | −$0.16 | +27.3% |
| Mar 2026 | −$0.20 | −$0.10 | +50.0% |
| Nov 2025 | −$0.22 | −$0.21 | +4.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Apr 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.20 | — | — | — | — | — | — |
| Aug 13, 2026 | −$0.16 | −$0.27 | −70.9% | — | — | — | −4.3% |
| May 13, 2026 | −$0.22 | −$0.16 | +27.3% | — | — | — | +1.8% |
| Mar 19, 2026 | −$0.20 | −$0.10 | +50.0% | — | — | — | +1.1% |
| Nov 14, 2025 | −$0.22 | −$0.21 | +4.5% | — | — | — | −8.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 19, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 30, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 24, 2022 | |||||||
| Nov 11, 2021 | |||||||
| Aug 12, 2021 | |||||||
| May 13, 2021 | |||||||
| Mar 30, 2021 | |||||||
| Nov 16, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 15, 2020 | |||||||
| Mar 17, 2020 | |||||||
| Nov 13, 2019 | |||||||
| Aug 13, 2019 | |||||||
| May 14, 2019 | |||||||
| Mar 28, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 11, 2018 | |||||||
| Apr 2, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 3, 2017 | |||||||
| Mar 3, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 10, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 10, 2015 | |||||||
| Aug 12, 2015 | |||||||